Streetbeat News

Stock Prices

ALB

Albemarle (NYSE: ALB) reported Q2 2024 earnings of $0.04 per share, missing the analyst estimate of $0.41 by 90.24%. Sales were $1.430 billion, beating the estimate of $1.338 billion by 6.88%. Compared to the same period last year, earnings decreased by 99.45% and sales by 39.66%.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:17 pm

FICO

FICO has raised its guidance, indicating improved financial performance expectations.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:17 pm

MET

MetLife (NYSE:MET) reported Q2 2024 adjusted earnings per share (EPS) of $2.28, surpassing the analyst consensus estimate of $2.11 by 8.06%.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:16 pm

CVNA

Carvana (NYSE:CVNA) reported Q2 2024 earnings per share (EPS) of $0.14, significantly beating the analyst consensus estimate of $(0.12) by 216.67%. The company also reported quarterly sales of $3.410 billion, surpassing the estimate of $3.244 billion by 5.12%. This marks a 14.89% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:16 pm

NE

Noble Corp (NYSE:NE) reported Q2 2024 adjusted earnings per share (EPS) of $0.72, surpassing the analyst consensus estimate of $0.60 by 20%. This represents an 89.47% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:15 pm

WDC

Western Digital has announced its Q1 adjusted EPS forecast of $1.55-$1.85, surpassing the estimated $1.18. Additionally, the company projects revenue between $4.00 billion and $4.20 billion, exceeding the estimated $3.747 billion.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:15 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) reported Q2 earnings per share (EPS) of $(1.70), missing the analyst estimate of $(1.66) by 2.41%. Quarterly sales were $8.65 million, also missing the estimate of $8.85 million by 2.19%. Despite the misses, both EPS and sales showed significant improvement compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:14 pm

SDGR

Schrödinger (SDGR) projects FY 2024 software revenue growth of 6%-13% and drug discovery revenue between $30M-$35M. The company expects a slight decrease in software gross margin compared to 2023, with operating expenses growing by 8%-10%. Cash used for operating activities is anticipated to be higher than in 2023. For Q3, software revenue is estimated to be $32M-$34M.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:14 pm

SNBR

Sleep Number (NASDAQ:SNBR) reported Q2 2024 GAAP EPS of $(0.22), beating the $(0.40) estimate, but sales of $408.413M missed the $415.039M estimate. EPS decreased by 833.33% YoY, and sales decreased by 10.98% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:14 pm

CFLT

Confluent (NASDAQ:CFLT) reported Q2 2024 adjusted EPS of $0.06, beating the estimate of $0.05. Sales were $235 million, surpassing the $229.978 million estimate and marking a 24.15% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:14 pm